US FDA approves Genzyme's Synvisc-One for osteoarthritis
This article was originally published in Scrip
Executive Summary
The US FDA has approved Genzyme's viscosupplement Synvisc-One (hylan G-F 20) for the relief of pain associated with osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapies and simple analgesics.